Xenon shareholders approve 5.3M share equity plan increase; all director nominees elected

Xenon Pharmaceuticals Inc.

Amendment to 2014 Equity Plan approved: 35.6M for, 6.2M against, 5.1M broker non-votes.
Total share reserve under plan increased to ~13.37M shares (includes prior reserves and 5.3M addition).
All eight director nominees elected with strong majority (e.g., Simon Pimstone 40.9M for).
Say-on-pay advisory vote passed: 41.1M for, 0.6M against.
KPMG reappointed as auditor with 45.9M for, 1.0M withheld.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.